Meeting
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
Authors
Atsushi Ishiguro
Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan
Atsushi Ishiguro , Hiroshi Nakatsumi , Kazuaki Harada , Satoshi Yuki , Kentaro Sawada , Susumu Sogabe , Takayuki Ando , Yusuke Sasaki , Ayumu Yoshikawa , Michio Nakamura , Masayoshi Dazai , Miki Tateyama , Osamu Muto , Masahito Kotaka , Tamotsu Sagawa , Kazuteru Hatanaka , Ryo Takagi , Yuh Sakata , Yoshito Komatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs011190006
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 113)
DOI
10.1200/JCO.2024.42.3_suppl.113
Abstract #
113
Poster Bd #
G17
Abstract Disclosures
Similar Posters
![BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAF<sup>V600E</sup> mCRC.](https://d201v5jt9ylckg.cloudfront.net/199/11943/153243/153243_poster_pv.jpg)
First Author: Sanne Huijberts
Poster
2023 ASCO Annual Meeting
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.
First Author: Veronica Conca
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2022 ASCO Annual Meeting
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
First Author: Jean-Louis Legoux